Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PYPD vs PASG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PYPD Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–1 Matrix Metrics)

PYPD Overall Winner 6-Pillar Tally: PYPD 2 – 2 PASG (2 Tie) Matrix Metrics: PYPD 4 – 1 PASG

As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Passage Bio, Inc. (PASG) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas PASG carries 21.6/100 (STRONG SELL) at $4.20 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both PYPD (31.1/100 SELL) and PASG (21.6/100 STRONG SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PYPD vs PASG
PYPD NASDAQ Head-to-Head Winner
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.43
+4.63% 1D
Market Cap $132.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.89β · 59% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 63
RSI-14: 63.2 · SMA20: $5.80 · SMA50: $5.40
PASG NASDAQ
Passage Bio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.20
+1.57% 1D
Market Cap $13.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.69β · 92% Vol
Unified Composite Score
21.6 / 100 STRONG SELL
Tech 3.0 Fund 31.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.0 · SMA20: $3.63 · SMA50: $4.08

6-Pillar Scorecard Institutional Category Breakdown (PYPD 2 – 2 PASG)

Columns: Metric · PYPD · PASG
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PYPD
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $132.2M $13.7M
3. Profitability & Quality PASG
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -243.6% -212.3%
4. Balance Sheet & Cash Flow PASG
Cash Generation (TTM) N/A -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.0M Net Cash $28M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PYPD
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 106.3% (12th %ile) 0.0% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PYPD (4) vs PASG (1)
Institutional Metric PYPD PASG Criterion Row Edge
Market Capitalization
Scale
$132.2M $13.7M Larger Scale PYPD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-243.6% -212.3% Higher ROE PASG
52-Week Range Position
Momentum
80% ($4–$7) 5% ($3–$20) Stronger Trend PYPD
Beta / 30D Volatility
Risk Regime
0.89β · 59% Vol 1.69β · 92% Vol Lower Realized Risk PYPD
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL) 21.6 / 100 (STRONG SELL) Higher Composite PYPD
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.0M Net Cash) -$31M ($28M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PYPD +14.68 pp
PYPD: +31.86% · PASG: +17.18%
3M Horizon PYPD +35.42 pp
PYPD: +28.44% · PASG: -6.98%
6M Horizon PYPD +52.61 pp
PYPD: +35.19% · PASG: -17.42%
1Y Horizon PYPD +131.85 pp
PYPD: +79.25% · PASG: -52.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs PASG. Trailing 12-month operating profitability (PYPD 0.0% vs PASG 0.0%) and valuation multiples (PYPD N/M vs PASG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PYPD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-243.6% · N/M
PASG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-212.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PYPD BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV 106.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PYPD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PASG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.0%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PASG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PYPD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PASG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $13.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PYPD vs PASG Key Questions & Quantitative Answers

As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Passage Bio, Inc. (PASG) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas PASG carries 21.6/100 (STRONG SELL) at $4.20 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although PYPD compares more favorably head-to-head, both PYPD (31.1/100 SELL) and PASG (21.6/100 STRONG SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

PYPD leads the Growth & Scale pillar: PYPD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PASG at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PYPD generates N/A in USD-normalized revenue versus N/A for PASG. In operating R&D and SG&A reinvestment, PYPD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PASG.

PYPD and PASG trade at balanced relative valuation multiples. PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PASG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PYPD (-243.6% ROE) versus PASG (-212.3% ROE) capital efficiency.

In options market volatility and institutional positioning, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.89β · 59% Vol realized risk). By comparison, PASG carries 0.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.69β · 92% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.